Physicians' Academy for Cardiovascular Education
In this e-learning course, five important aspects of use of GLP-1RAs will be discussed. Member registration (free) is needed to enroll in this course.
5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.
5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.
5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.
There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.
In this e-learning course, the role of novel diabetes treatment approaches in the prevention of CVD in patients with T2DM will be discussed. Member registration (free) is needed to enroll in this course.
Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.
Jorge Plutzky describes potential mechanisms for the benefit of some GLP1-RA in CVOTs and discusses their possible effects on atherosclerosis in patients with diabetes.
This 2020 expert consensus decision pathway (ECDP) provides practical guidance on the use of SGLT2i and GLP-1RAs for reducing the risk of CVD in patients with T2DM.
Prof. Landmesser discusses with professors Marx, Plutzky and Deanfield how to implement new therapies to reduce CV risk in patients with diabetes.
